First myostatin-targeted antibody approved for spinal muscular atrophy
2026-09-18
Asher Mullard
DOI: 10.1038/d41573-026-00152-z← Back to Journals
Feed status
8 parsed articles
Last update: 2026-09-21
Latest articles
The value of speed for drug developers
2026-09-18
David B. Ridley, Chenxi Xu
DOI: 10.1038/d41573-026-00149-8Selective oestrogen receptor degrader class grows with new cancer approval
2026-09-11
Asher Mullard
DOI: 10.1038/d41573-026-00151-0A translational framework for extrahepatic oligonucleotide delivery
2026-09-09
Łukasz Jan Kiełpiński, Felix Franz Schumacher
To unlock the ‘plug-and-play’ potential of extrahepatic delivery of oligonucleotide-based drugs, the field must bridge the gap between preclinical promise and clinical reality. Here, we outline an industry-grade quality framework to eliminate methodological artifacts and ensure the translational and commercial viability of novel platforms.
DOI: 10.1038/d41573-026-00125-2Upcoming FDA approval decisions in Q4 2026
2026-09-09
Kaniaw Dilzer
DOI: 10.1038/d41573-026-00150-1Strengthening muscle for healthy ageing: innovative treatments for sarcopenia
2026-09-07
Sara Ancel, Emmeran Le Moal, Yu Xin Wang, Helen M. Blau
There are currently no approved therapies for sarcopenia, the age-related loss of skeletal muscle mass and strength. This Review discusses advances in understanding of the cellular, molecular and metabolic mechanisms driving muscle wasting with ageing, while assessing emerging therapeutic approaches and agents in development.
DOI: 10.1038/s41573-026-01514-3Un-siloed biomedical opportunities
2026-09-07
Asher Mullard
Edith Heard, CEO of the Francis Crick Institute, discusses the need to break down biomedical boundaries.
DOI: 10.1038/d41573-026-00148-9Newest glue degrader nabs multiple myeloma approval
2026-09-04
Asher Mullard
DOI: 10.1038/d41573-026-00147-w